ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence
and clinical research organisation, today releases its ICON Cares
2022 Environmental, Social and Governance (ESG) Report. The
company’s ICON Cares initiative incorporates its ESG, Diversity,
Inclusion and Belonging and Corporate Social Responsibility
initiatives under one program.
The report provides an overview of ICON’s ESG activities in 2022
and the progress it has made in advancing its ESG priorities. These
priorities include advancing public health and delivering increased
access to clinical trials, providing a diverse and inclusive
workplace with continuous opportunities for professional
development and conducting business sustainably.
In recognition of progress made in its ESG efforts, in 2022,
ICON was awarded a silver medal by EcoVadis, a leading provider of
business sustainability ratings. ICON’s score positioned the
company in the 87th percentile of firms assessed by EcoVadis. To
drive further progress on reducing GHG emissions, in April 2023,
ICON signed its commitment letter to the Science Based Targets
initiative (SBTi) as a first step in setting science-based climate
targets.
On the publication of the report, Dr Steve Cutler, CEO, ICON
commented: “This report shows what we can achieve for our
customers, people, patients and communities as a leader in our
industry. Our ESG priorities are in areas where we believe we can
deliver the greatest impact, and we have made important progress
toward these goals. Every advancement is underpinned by the energy,
ambition and delivery of our global staff. I am highly encouraged
as to what more we can accomplish in the future.”
Advancing public health and increased access to clinical
trials
ICON has focused on creating a strong foundation that enables
the execution of new and innovative methods for meeting patient
needs and advancing public health. It is focusing its innovation
efforts in three critical areas - improving clinical trial design
and execution, enabling faster and more predictable patient
recruitment, and evolving clinical trials to be more
patient-centric.
Examples of activities in 2022 in this regard include:
- ICON released a major artificial intelligence enhancement to
its proprietary OneSearch tool, which identifies the best sites for
a trial opportunity. The results include significantly improved
study start-up and site cycle times.
- In partnership with Veradigm, a health information technology,
analytics and intervention solutions company, ICON created an
electronic health records-based clinical research network. The
partnership enables clinical research as a care option, which can
help reach more diverse populations, increase recruitment rates and
accelerate time-to-market for new therapies.
An inclusive workplace with continuous access to professional
development
ICON continued its focus on building a diverse and inclusive
workforce that provides professional advancement and career
opportunities for its people. As an example of progress in this
regard, in 2022, 59% of all promotions at VP level and above were
female, bringing the total number of females at the VP level and
above to 42%. This is important progress toward its goal to achieve
gender parity at the VP level and above by 2025.
Conducting business sustainably
ICON is actively managing its environmental impact across its
global business. Progress made in 2022 included:
- 61.7% of electricity consumed in 2022 came from renewable
sources
- ICON’s combined Scope 1 and 2 GHG emissions decreased by 23.5%
since 2018 and 10% since 2021
- 10% reduction in kilowatt hours of electricity since 2018
Strengthening communities
The report also outlines how ICON supports communities through
corporate giving programs, employee volunteering opportunities and
industry–academia partnerships. The company has aligned its efforts
to the United Nations Sustainable Development Goals and its
organisational goals of diversity, inclusion and belonging.
In 2022, ICON created a new scholarship program to provide
greater opportunities for underrepresented groups to study STEM
subjects. For the 2022/2023 academic year, ICON is funding 33
scholarships for STEM course students in partnership with three
universities in Ireland and the Thurgood Marshall College Fund in
the US. The latter is a not-for-profit organisation that supports
nearly 300,000 students attending its 47 member schools, including
publicly supported Historically Black Colleges and
Universities.
For further information about ICON’s ESG efforts, please visit
www.iconplc.com/about/esg/.
Ends
This press release contains forward-looking statements,
including statements about our financial guidance. These statements
are based on management's current expectations and information
currently available, including current economic and industry
conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, the impact of
COVID-19 on our business, as well as other economic and global
market conditions and other risks and uncertainties detailed from
time to time in SEC reports filed by ICON, all of which are
difficult to predict and some of which are beyond our control. For
these reasons, you should not place undue reliance on these
forward-looking statements when making investment decisions. The
word "expected" and variations of such words and similar
expressions are intended to identify forward-looking statements.
Forward-looking statements are only as of the date they are made
and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information,
future events or otherwise. More information about the risks and
uncertainties relating to these forward-looking statements may be
found in SEC reports filed by ICON, including its Form 20-F, F-1,
F-4, S-8, F-3 and certain other reports, which are available on the
SEC's website at http://www.sec.gov.
About ICON plc
ICON plc is a world-leading healthcare intelligence and clinical
research organisation. From molecule to medicine, we advance
clinical research providing outsourced services to pharmaceutical,
biotechnology, medical device and government and public health
organisations. We develop new innovations, drive emerging therapies
forward and improve patient lives. With headquarters in Dublin,
Ireland, ICON employed approximately 41,150 employees in 109
locations in 53 countries as at March 31, 2023. For further
information about ICON, visit: www.iconplc.com.
ICON/ICLR-G
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230516005178/en/
Media contacts: Claire Quinn Corporate Communications,
ICON +353 87 4066091 claire.quinn@iconplc.com
Weber Shandwick (PR adviser) Lisa Henry +44 7785 458203
lhenry@webershandwick.com
Kate Haven Vice President Investor Relations, ICON
+1-888-381-7923 IR@iconplc.com
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024